Revolution Medicines, Inc. Announces \$500 Million Convertible Notes Offering

Key Highlights from the Recent SEC Filing

• Revolution Medicines, Inc. (Nasdaq: RVMD) has entered into an underwriting agreement to issue and sell \$500 million aggregate principal amount of convertible senior notes due 2031.
• The joint book-running managers for the offering are J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC. LifeSci Capital LLC is acting as lead manager.
• The Notes carry a stated interest rate of 0.50% per annum, payable semi-annually on May 1 and November 1, beginning November 1, 2026.
• Initial conversion price: Approximately \$198.80 per share, representing a 40% premium over the public offering price of the company’s common stock in the concurrent equity offering.
• Initial conversion rate: 5.0302 shares of common stock per \$1,000 principal amount of Notes.
• Settlement date: April 16, 2026.
• Use of proceeds: Estimated net proceeds from the convertible notes and concurrent common stock offering will be used for general corporate purposes, including clinical development, preclinical research and development, working capital, and capital expenditures.
• The company has granted underwriters the option to purchase additional shares of common stock in the concurrent equity offering.
• The Notes will be listed on the Nasdaq Stock Market LLC under the symbol “RVMD”.
• The company has agreed to indemnify underwriters against certain liabilities, including under the Securities Act of 1933.
• The Notes offering and the concurrent common stock offering are expected to close on April 16, 2026, subject to customary closing conditions.

Details for Investors

The Notes will be senior, unsecured obligations of Revolution Medicines, Inc., and will mature on May 1, 2031, unless earlier repurchased, redeemed, or converted. The company may redeem all or part of the Notes for cash at its option on or after May 6, 2029, at a redemption price equal to 100% of the principal amount, plus accrued and unpaid interest.

Conversion rights: Holders can convert their Notes into shares of common stock at the initial conversion rate, subject to adjustment upon certain events. If a “make-whole fundamental change” occurs, the conversion rate may be increased for holders who convert their Notes in connection with such an event.

Potential dilution: If all Notes are converted, this could result in the issuance of a substantial number of new shares, potentially diluting existing shareholders. The 40% conversion premium means the Notes are initially convertible at a price significantly higher than the current market price, but any sharp rise in the share price could trigger conversions.

No stabilization or manipulation: The company and its affiliates have agreed not to take actions to stabilize or manipulate the price of the securities.

Lock-up period: The company and its directors, executive officers, and certain significant shareholders have agreed to a 45-day “lock-up” period, restricting sales or hedging of the company’s securities, except under limited circumstances.

Financial position and use of proceeds: The proceeds are expected to support the company’s ongoing R&D and clinical programs, potentially accelerating pipeline development and strengthening the balance sheet.

Price-Sensitive Information Impacting Shareholders

• Significant capital raise: The \$500 million convertible notes offering is a substantial financing event that will provide Revolution Medicines with increased liquidity and flexibility to pursue its strategic objectives.
• Potential dilution: The conversion feature, if exercised, could dilute existing shareholders, especially if the share price rises above the conversion price.
• Low interest rate: The 0.50% coupon is attractive from a cost-of-capital perspective, but may also indicate strong demand for the company’s securities and investor confidence in future growth prospects.
• Indemnification of underwriters: Standard for such transactions, but noteworthy for risk disclosure purposes.
• Lock-up agreements: These can help support the share price in the near term by limiting supply.
• No ratings: The Notes are not rated by a nationally recognized statistical rating organization.

Other Notable Disclosures

• The company and its subsidiaries have affirmed there are no material undisclosed adverse changes, legal proceedings, or regulatory issues that could affect the company’s business or financial position at this time.
• The company is in compliance with all relevant statutes, rules, and regulations, including Sarbanes-Oxley, the USA Patriot Act, and applicable SEC and Nasdaq requirements.
• The offering has been registered with the SEC under Registration Statement No. 333-277640.
• The company has robust internal controls over financial reporting and no material weaknesses in those controls have been identified.

Conclusion

Investor Takeaway: Revolution Medicines, Inc. is undertaking a significant capital markets transaction with the offering of \$500 million in convertible notes, alongside a concurrent common stock offering. The low coupon, conversion premium, and use of proceeds for R&D and corporate purposes reflect both strong investor demand and the company’s growth ambitions. However, shareholders should monitor the potential for future dilution and the impact of the new capital on Revolution Medicines’ strategic execution and share price performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should read the full SEC filings and consult their financial advisors before making any investment decisions. The information herein is based on publicly available documents and may not contain all material information about Revolution Medicines, Inc. or the described securities offerings.

View Revolution Medicines, Inc. Historical chart here